JY BioMedical Secures Provisional Patent for Revolutionary Gamma Delta T Cell Immunotherapy Production Method
- 博翔(Benjamin) 張
- Jan 7
- 2 min read
JY BioMedical is proud to announce the successful submission of a provisional patent application to the United States Patent and Trademark Office (USPTO) for its groundbreaking invention: a novel method for the production of Gamma Delta (γδ) T cells for immunotherapy applications. The application, filed under attorney docket number G4590-21200P, represents a significant milestone in advancing cell-based cancer immunotherapy.
The patent, titled "Method for the Production of Gamma Delta T Cells for Immunotherapy Applications," focuses on an optimized process for isolating, expanding, and activating Vδ2+ γδ T cells from peripheral blood mononuclear cells (PBMCs). By employing advanced immunomagnetic separation techniques and serum-free mediums supplemented with growth factors such as interleukin-2 (IL-2) and interleukin-15 (IL-15), this method achieves high cell viability and enhanced therapeutic-grade γδ T cell populations.
Key Features of the Invention Include:
High Purity and Viability: Enriched Vδ2+ γδ T cell populations exceed 95% purity with over 90% viability post-expansion.
Scalable Manufacturing: A reproducible process suitable for clinical-grade production under Good Manufacturing Practices (GMP).
Enhanced Anti-Tumor Efficacy: Potent cytotoxic activity against various cancer cell lines, including breast, liver, and lung cancers, as demonstrated in preclinical studies.
“Securing this provisional patent underscores our commitment to innovating next-generation cancer therapies,” said Dr. Benjamin Zhang, Chief Medical Officer and inventor of the patent at JY BioMedical. “Gamma Delta T cells offer a promising avenue for treating both solid tumors and hematological malignancies, and this invention brings us closer to realizing their full potential.”
Dr. Zhang, a pioneer in immunotherapy, has been instrumental in leading this breakthrough innovation, leveraging his expertise to develop a method that ensures both scalability and clinical efficacy. This filing reflects JY BioMedical's dedication to advancing the field of cell-based immunotherapy.
About JY BioMedical
JY BioMedical is a leading biotechnology company dedicated to developing transformative cell and gene therapies. Our mission is to harness cutting-edge science to create impactful solutions for cancer and immune-related diseases.
For further information, please contact: service@jy-biomed.com
Comments